Skip to content

Abstract 8806: Comparative Efficacy of GLP-1 Receptor Agonists versus SGLT-2 Inhibitors for Limb Outcomes in Patients with Peripheral Artery Disease: A Multicenter Propensity Score-Matched Real-World Study

Nov 2026 · Circulation · 0 citations

Abstract

Background: Patients with peripheral artery disease (PAD) face high risks of limb loss, revascularization, and cardiovascular events. While both GLP-1 receptor agonists (GLP-1 RAs) and SGLT-2 inhibitors (SGLT-2is) improve cardiovascular outcomes in type 2 diabetes, their comparative effectiveness on limb-specific outcomes in broad PAD populations remains unclear. We compared GLP-1 RAs versus SGLT-2is on limb and cardiovascular outcomes in real-world patients with PAD. Methods: In this retrospective multicenter study using the TriNetX US Collaborative Network, adults with PAD (ICD-10-CM I73) who newly initiated a GLP-1 RA or SGLT-2i were identified. Patients with prior exposure to the comparator drug were excluded. Propensity score matching (1:1) was performed on 44 covariates including demographics, comorbidities, medications, and laboratory values. Outcomes from day 1 to 730 (upto 2-year) post-index included major lower-extremity amputation, chronic limb ischemia, endovascular revascularization, progression of extremity atherosclerosis, all-cause hospitalization, major adverse cardiovascular events (MACE), and all-cause mortality. Analyses used Kaplan-Meier estimates, Cox proportional hazards models, and multivariable adjustment. Results: Post-matching, cohorts comprised 51,995 patients per group for 1-year and 55,238 per group for 2-year analyses, achieving excellent covariate balance (standardized mean differences <0.10 for most variables). Compared with SGLT-2is, GLP-1 RAs were associated with significantly lower 1-year risks: all-cause mortality (4.53% vs 6.10%; HR 0.704, 95% CI 0.667-0.742), major amputation (1.15% vs 1.43%; HR 0.770, 95% CI 0.691-0.858), all-cause hospitalization (21.53% vs 30.22%; HR 0.644, 95% CI 0.628-0.660), MACE (11.24% vs 14.93%; HR 0.703, 95% CI 0.680-0.728), chronic limb ischemia (2.48% vs 2.63%; HR 0.907, 95% CI 0.840-0.978), endovascular revascularization (2.17% vs 2.70%; HR 0.770, 95% CI 0.712-0.833), and progression of extremity atherosclerosis (10.89% vs 12.54%; HR 0.829, 95% CI 0.800-0.859); all log-rank p<0.05. Similar relative risk reductions persisted at 2 years (mortality HR 0.772; amputation HR 0.816). In multivariable Cox regression adjusting for sex, CKD, diabetes, BMI, LVEF, and other factors, GLP-1 RA use remained independently associated with markedly lower mortality (adjusted HR 0.460, 95% CI 0.438-0.483, p<0.0001). Conclusions: In this large propensity score-matched real-world study of patients with PAD, GLP-1 RAs were associated with substantially lower risks of major limb events, revascularization, atherosclerotic progression, hospitalization, MACE, and mortality compared with SGLT-2is. These findings support the preferential consideration of GLP-1 RAs for vascular risk reduction in PAD, pending confirmation by randomized trials.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.